Liraglutide Audit DUK Annual Professional Conference, Manchester, March 13, 2013 - Slides

Does Liraglutide therapy affect the metabolic response in patients with elevated alanine aminotransferase and type 2 diabetes mellitus?

Piya Sen Gupta1, ABCD Research Fellow KY Thong1, M Cull1, P Winocour2, REJ Ryder1 on behalf of the ABCD nationwide liraglutide audit contributors

1City Hospital, Birmingham, UK

2QE 2 Hospital, Welwyn Garden City, UK

Discipline

Diabetes
Resource taxonomy
Audit Slides
Clinical taxonomy
Treatments for diabetes Type 2 diabetes mellitus
Listing status
Archived

ABCD Corporate Pharma Sponsors

Gold

  • AstraZeneca UK
  • Boehringer Ingelheim and Lilly Alliance
  • Eli Lilly and Company

Silver

  • A Menarini Farmaceutica Internazionale SRL
  • Sanofi

ABCD Corporate Pump & Device Sponsors

Gold

  • Abbott
  • Dexcom
  • Ypsomed Ltd

Silver

  • A. Menarini Diagnostics
  • Advanced Therapeutics (UK) Ltd
  • Air Liquide Healthcare Ltd
  • Insulet International
  • Medtronic Limited

Bronze

  • Roche Diabetes Care

Contact

Address for correspondence: 
ABCD (Diabetes Care) Ltd, 483 Green Lanes, London, N13 4BS

Telephone: 01675 477602
Email: info@abcd.care

Follow Us

ABCD (Diabetes Care) is a company limited by shares in England and Wales under company number 7270377, whose registered address is Fifteen Rosehill, Montgomery Way, Rosehill Estate, Carlisle CA1 2RW Diabetes Care Trust (ABCD) is a registered charity number 1139057, a company limited by guarantee in England and Wales under company number 74248361, whose registered address is Fifteen Rosehill, Montgomery Way, Rosehill Estate, Carlisle CA1 2RW. ABCD (Diabetes Care) Ltd is a wholly owned subsidiary of the Diabetes Care Trust (ABCD) Ltd